

# Roy M Fleischmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5568624/publications.pdf>

Version: 2024-02-01

183  
papers

20,865  
citations

25034

57  
h-index

9589

142  
g-index

183  
all docs

183  
docs citations

183  
times ranked

10229  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 1477-1483.	3.4	1
2	Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. <i>Journal of Rheumatology</i> , 2022, 49, 133-141.	2.0	5
3	Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. <i>Rheumatology</i> , 2022, 61, 2413-2423.	1.9	25
4	Benefitâ€Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 191-206.	2.3	4
5	Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2022, 386, 316-326.	27.0	640
6	Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. <i>RMD Open</i> , 2022, 8, e002012.	3.8	50
7	Recent issues in JAK inhibitor safety: perspective for the clinician. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 295-307.	3.0	11
8	Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 649-661.	2.3	1
9	Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 839-850.	2.3	4
10	Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. <i>RMD Open</i> , 2022, 8, e001994.	3.8	15
11	Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 435-446.	2.3	4
12	Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. <i>Lancet Rheumatology</i> , The, 2022, 4, e395-e406.	3.9	4
13	OA27â€fSustainability of response between upadacitinib and adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE trial. <i>Rheumatology</i> , 2022, 61, .	1.9	0
14	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
15	Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 432-439.	0.9	14
16	Tofacitinib monotherapy in psoriatic arthritisâ€”what is missing?. <i>Lancet Rheumatology</i> , The, 2021, 3, e3-e5.	3.9	0
17	Upadacitinib improves patient-reported outcomes <i>vs</i> placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. <i>Rheumatology</i> , 2021, 60, 5583-5594.	1.9	17
18	Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26â€52, including a treatment switch from reference ADL to PF-06410293. <i>RMD Open</i> , 2021, 7, e001578.	3.8	10

#	ARTICLE	IF	CITATIONS
19	P134â€fRadiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with RA: results from RA-BEYOND. Rheumatology, 2021, 60, .	1.9	0
20	The Results of Well-conducted Negative Clinical Trials Should Be Reported in a Peer-reviewed Journal. Journal of Rheumatology, 2021, 48, jrheum.201622.	2.0	0
21	Current Treatment Strategies in Rheumatoid Arthritis After Methotrexate Are Not Enough to Maintain Sustained Remission: There Is No Holy Grail!. Arthritis and Rheumatology, 2021, 73, 1124-1126.	5.6	0
22	Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors. Rheumatology, 2021, 60, 4991-5001.	1.9	11
23	A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?. Arthritis and Rheumatology, 2021, 73, 2166-2178.	5.6	43
24	Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. RMD Open, 2021, 7, e001609.	3.8	4
25	Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. Arthritis Research and Therapy, 2021, 23, 220.	3.5	2
26	Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52â€“92 data from a randomized, double-blind, phase 3 trial. Arthritis Research and Therapy, 2021, 23, 248.	3.5	9
27	Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis. Clinical Rheumatology, 2021, 40, 4369-4372.	2.2	0
28	Efficacy and Safety of Longâ€Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate. Arthritis Care and Research, 2020, 72, 1112-1121.	3.4	25
29	Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. Arthritis Care and Research, 2020, 72, 353-359.	3.4	23
30	Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 yearsâ€™ follow-up. Rheumatology, 2020, 59, 292-302.	1.9	43
31	Looking Back on 2019 in Rheumatology and What to Expect from 2020. Rheumatology and Therapy, 2020, 7, 1-3.	2.3	0
32	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open, 2020, 6, e001374.	3.8	36
33	EULAR PsA management recommendations 2019: can the recommendations be improved?. Annals of the Rheumatic Diseases, 2020, 79, 700.2-712.	0.9	5
34	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 1290-1297.	0.9	61
35	Interleukin-6 receptor blockade or TNF± inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Research and Therapy, 2020, 22, 206.	3.5	20
36	Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Research and Therapy, 2020, 22, 139.	3.5	21

#	ARTICLE	IF	CITATIONS
37	Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis. Expert Opinion on Drug Safety, 2020, 19, 935-944.	2.4	8
38	Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial. Rheumatology and Therapy, 2020, 7, 327-344.	2.3	25
39	Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis. Journal of Clinical Medicine, 2020, 9, 2017.	2.4	0
40	Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology, 2020, 59, 2774-2784.	1.9	31
41	Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. Rheumatology and Therapy, 2020, 7, 35-64.	2.3	49
42	2019 update of the American College of Rheumatology's recommended rheumatoid arthritis disease activity measures: comment on the article by England et al. Arthritis Care and Research, 2020, 72, 736-736.	3.4	4
43	Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation? Comment on article by Boeters DM et al.. Arthritis Research and Therapy, 2020, 22, 17.	3.5	3
44	Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. Drugs in Context, 2020, 9, 1-15.	2.2	6
45	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. Clinical and Experimental Rheumatology, 2020, 38, 848-857.	0.8	6
46	Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis and Rheumatology, 2019, 71, 1788-1800.	5.6	284
47	Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). Rheumatology and Therapy, 2019, 6, 559-571.	2.3	15
48	Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Annals of the Rheumatic Diseases, 2019, 78, 1454-1462.	0.9	115
49	Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. Arthritis Research and Therapy, 2019, 21, 231.	3.5	6
50	Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis. Rheumatology, 2019, 58, .	1.9	1
51	Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors. Rheumatology, 2019, 58, .	1.9	0
52	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis and Rheumatology, 2019, 71, 878-891.	5.6	64
53	Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. Journal of Clinical Medicine, 2019, 8, 831.	2.4	50
54	Long-term safety with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9,000 patient-years of follow-up. Rheumatology, 2019, 58, .	1.9	1

#	ARTICLE	IF	CITATIONS
55	Value of the Multibiomarker Disease Activity Score to Predict Remission in RA: What Does the Evidence Show?. Journal of Rheumatology, 2019, 46, 443-446.	2.0	8
56	Effect of sarilumab on glycosylated hemoglobin in patients with rheumatoid arthritis and diabetes. Rheumatology, 2019, 58, .	1.9	1
57	THU0170A...A MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF REPOSITORY CORTICOTROPIN INJECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: INTERIM DATA FROM THE OPEN-LABEL TREATMENT PERIOD. , 2019, , .		0
58	THU0193A...EFFICACY OF TOFACITINIB MONOTHERAPY, TOFACITINIB WITH METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE IN PATIENTS WITH EARLY (<2 YEARS) VS ESTABLISHED (>2 YEARS) RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STRATEGY. , 2019, , .		3
59	THU0075A...EARLY VERSUS DELAYED START OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A PHASE 3 TRIAL OF PATIENTS NAïVE TO METHOTREXATE TREATMENT. , 2019, , .		1
60	Dr. Fleischmann replies. Journal of Rheumatology, 2019, 46, 1642.2-1642.	2.0	0
61	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open, 2019, 5, e001040.	3.8	28
62	Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1 $\alpha$ and anti-interleukin-1 $\beta$ dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 413-420.	0.9	115
63	A Summary of 2018 and What Lies Ahead for Rheumatology and Therapy in 2019. Rheumatology and Therapy, 2019, 6, 1-3.	2.3	0
64	A Phase II/III Trial of Lutikizumab, an Anti-Interleukin-1 $\alpha$ /1 $\beta$ Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis and Rheumatology, 2019, 71, 1056-1069.	5.6	137
65	Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis. Rheumatology and Therapy, 2018, 5, 283-291.	2.3	62
66	Editorial: The American College of Rheumatology White Paper on Biosimilars: It Isn't All White—There Is Some Gray and Black. Arthritis and Rheumatology, 2018, 70, 323-325.	5.6	16
67	Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatology and Therapy, 2018, 5, 203-214.	2.3	10
68	4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open, 2018, 4, e000582.	3.8	34
69	Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open, 2018, 4, e000584.	3.8	33
70	Tofacitinib in the treatment of active rheumatoid arthritis in adults. Immunotherapy, 2018, 10, 39-56.	2.0	12
71	Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. Journal of Rheumatology, 2018, 45, 177-187.	2.0	18
72	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 289-292.	0.9	22

#	ARTICLE	IF	CITATIONS
73	223â€fSustained response in a phase III study of sarilumab plus nonbiologic disease modifying anti-rheumatic drugs in patients with active, moderate-to-severe rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Rheumatology, 2018, 57, .	1.9	1
74	A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Seminars in Arthritis and Rheumatism, 2018, 48, 406-415.	3.4	32
75	217â€fImprovements in remission and low disease activity are achieved with ongoing sarilumab treatment, in patients with rheumatoid arthritis in two phase III studies. Rheumatology, 2018, 57, .	1.9	0
76	Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study. Clinical Rheumatology, 2018, 37, 2381-2390.	2.2	26
77	Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open, 2018, 4, e000656.	3.8	90
78	A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis. Arthritis Research and Therapy, 2018, 20, 178.	3.5	44
79	Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet, The, 2018, 391, 2513-2524.	13.7	316
80	Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study. RMD Open, 2018, 4, e000647.	3.8	11
81	Interleukin-6 inhibition for rheumatoid arthritis. Lancet, The, 2017, 389, 1168-1170.	13.7	7
82	DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open, 2017, 3, e000382.	3.8	71
83	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitorâ€methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open, 2017, 3, e000371.	3.8	26
84	Reply. Arthritis and Rheumatology, 2017, 69, 867-868.	5.6	3
85	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet, The, 2017, 390, 457-468.	13.7	360
86	Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. RMD Open, 2017, 3, e000416.	3.8	33
87	Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients. Rheumatology and Therapy, 2017, 4, 57-69.	2.3	11
88	A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. Expert Opinion on Pharmacotherapy, 2017, 18, 1525-1533.	1.8	19
89	Safety, Tolerability, and Pharmacodynamics of <sc>ABT</sc>â€122, a Tumor Necrosis Factorâ€ and Interleukinâ€17â€Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 2283-2291.	5.6	27
90	Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. RMD Open, 2017, 3, e000546.	3.8	39



#	ARTICLE	IF	CITATIONS
91	Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis and Rheumatology, 2017, 69, 277-290.	5.6	146
92	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. Arthritis and Rheumatology, 2017, 69, 506-517.	5.6	310
93	Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open, 2017, 3, e000491.	3.8	33
94	Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Research and Therapy, 2017, 19, 208.	3.5	48
95	Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab. Arthritis and Rheumatology, 2016, 68, 2083-2089.	5.6	42
96	Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open, 2016, 2, e000308.	3.8	50
97	Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. RMD Open, 2016, 2, e000210.	3.8	3
98	Efficacy of tofacitinib monotherapy in methotrexate-naïve patients with early or established rheumatoid arthritis. RMD Open, 2016, 2, e000262.	3.8	24
99	Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis. RMD Open, 2016, 2, e000232.	3.8	16
100	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology, 2016, 55, 1031-1041.	1.9	62
101	Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. International Journal of Rheumatic Diseases, 2016, 19, 1216-1225.	1.9	26
102	Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 907-913.	3.4	24
103	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet, The, 2016, 388, 2763-2774.	13.7	144
104	Reply to letter to the editor with regards to manuscript AR-15-1750.R1. Arthritis and Rheumatology, 2016, , .	5.6	0
105	Living with Psoriatic Arthritis: A Patient's and Physician's Perspective. Rheumatology and Therapy, 2016, 3, 1-4.	2.3	1
106	Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Annals of the Rheumatic Diseases, 2016, 75, 709-714.	0.9	134
107	Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2016, 75, 1293-1301.	0.9	61
108	Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III. Clinical and Experimental Rheumatology, 2016, 34, 32-6.	0.8	5

#	ARTICLE	IF	CITATIONS
109	Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 430-42.	0.8	23
110	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. <i>Arthritis Research and Therapy</i> , 2015, 17, 325.	3.5	16
111	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. <i>Arthritis Research and Therapy</i> , 2015, 17, 343.	3.5	13
112	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1424-1437.	5.6	213
113	Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. <i>Arthritis Research and Therapy</i> , 2015, 17, 307.	3.5	53
114	A Randomized, Double-blind, Placebo-controlled, Twelve-week, Dose-ranging Study of Decernotinib, an Oral Selective JAK3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 334-343.	5.6	98
115	Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib. <i>Arthritis and Rheumatology</i> , 2015, 67, 616-625.	5.6	157
116	Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. <i>Journal of Rheumatology</i> , 2015, 42, 1761-1766.	2.0	194
117	Developing new oral targeted therapies for RA can be challenging. <i>Nature Reviews Rheumatology</i> , 2015, 11, 4-6.	8.0	6
118	Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 538-546.	0.9	75
119	Response to: "Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry" by Favalli et al. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e6-e6.	0.9	1
120	How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1132-1137.	0.9	95
121	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1607-1615.	0.9	125
122	Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study. <i>Current Medical Research and Opinion</i> , 2014, 30, 2139-2149.	1.9	13
123	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760.	0.9	11
124	Sarilumab, a fully human monoclonal antibody against IL-6 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1626-1634.	0.9	173
125	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 86-94.	0.9	256
126	Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. <i>Rheumatology</i> , 2014, 53, 2167-2174.	1.9	92



#	ARTICLE	IF	CITATIONS
127	Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis. <i>Rheumatology</i> , 2014, 53, 1984-1993.	1.9	10
128	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet</i> , The, 2014, 383, 321-332.	13.7	232
129	Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e54-e54.	0.9	0
130	Tofacitinib versus Methotrexate in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2014, 370, 2377-2386.	27.0	630
131	86.â€fHead-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in Rheumatoid Arthritis: Blinded Two-Year Results from the Ample Study. <i>Rheumatology</i> , 2014, 53, i88-i88.	1.9	0
132	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2013, 159, 253.	3.9	381
133	Tofacitinib (CPâ€690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelveâ€month data from a twentyâ€fourâ€month phase III randomized radiographic study. <i>Arthritis and Rheumatism</i> , 2013, 65, 559-570.	6.7	481
134	Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results. <i>Journal of Rheumatology</i> , 2013, 40, 113-126.	2.0	87
135	Headâ€toâ€head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIb, multinational, prospective, randomized study. <i>Arthritis and Rheumatism</i> , 2013, 65, 28-38.	6.7	225
136	Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach. <i>Rheumatology</i> , 2013, 52, i44-i55.	1.9	2
137	Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trial. <i>Rheumatology</i> , 2013, 52, 409-410.	1.9	7
138	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: TableÂ1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.9	114
139	Novel small-molecular therapeutics for rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 335-341.	4.3	62
140	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012, 51, 2204-2214.	1.9	115
141	Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. <i>Arthritis Care and Research</i> , 2012, 64, 1794-1803.	3.4	149
142	Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 508-519.	27.0	810
143	Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 495-507.	27.0	826
144	Phase IIb doseâ€ranging study of the oral JAK inhibitor tofacitinib (CPâ€690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to diseaseâ€modifying antirheumatic drugs. <i>Arthritis and Rheumatism</i> , 2012, 64, 617-629.	6.7	339

#	ARTICLE	IF	CITATIONS
145	Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 373-382.	3.4	58
146	Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu. <i>Arthritis and Rheumatism</i> , 2011, 63, 609-621.	6.7	369
147	Don't forget traditional DMARDs. <i>Rheumatology</i> , 2011, 50, 429-430.	1.9	13
148	Kinase inhibitors: a new approach to rheumatoid arthritis treatment. <i>Current Opinion in Rheumatology</i> , 2010, 22, 330-335.	4.3	87
149	Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials. <i>Journal of Rheumatology</i> , 2010, 37, 558-567.	2.0	265
150	The efficacy and safety of golimumab in the treatment of arthritis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1131-1143.	3.1	3
151	Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 38, 265-280.	3.4	61
152	Golimumab, a human anti- $\alpha$ tumor necrosis factor $\beta$ monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2272-2283.	6.7	387
153	Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis. <i>BMC Musculoskeletal Disorders</i> , 2008, 9, 32.	1.9	16
154	Clinical studies can be performed in an ethical manner. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, E5-E5.	3.2	1
155	Primer: establishing a clinical trial unit—regulations and infrastructure. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 234-239.	3.2	6
156	Primer: establishing a clinical trial unit—obtaining studies and patients. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 459-463.	3.2	4
157	Pharmacokinetics and Safety of Golimumab, a Fully Human Anti-TNF- $\beta$ Monoclonal Antibody, in Subjects With Rheumatoid Arthritis. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 383-396.	2.0	172
158	Risk/Benefit Profile of Etanercept in Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis. <i>Drugs and Aging</i> , 2007, 24, 239-254.	2.7	56
159	Anakinra in the treatment of rheumatic disease. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 331-340.	3.0	14
160	Comparison of the Efficacy of Biologic Therapy for Rheumatoid Arthritis: Can the Clinical Trials Be Accurately Compared?. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 21-28.	1.9	10
161	Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. <i>Clinical Rheumatology</i> , 2006, 25, 42-53.	2.2	40
162	The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 1390-1400.	6.7	951

#	ARTICLE	IF	CITATIONS
163	Safety and efficacy of etanercept in the elderly. Aging Health, 2006, 2, 189-197.	0.3	3
164	Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. Journal of Rheumatology, 2006, 33, 234-43.	2.0	91
165	Treatment of early rheumatoid arthritis. Modern Rheumatology, 2005, 15, 153-162.	1.8	4
166	Treatment of early rheumatoid arthritis. Modern Rheumatology, 2005, 15, 153-162.	1.8	5
167	Is there a need for new therapies for rheumatoid arthritis?. Journal of rheumatology Supplement, The, 2005, 73, 3-7; discussion 29-30.	2.2	3
168	Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 1232-42.	2.0	89
169	Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opinion on Drug Safety, 2004, 3, 391-403.	2.4	56
170	Does safety make a difference in selecting the right TNF antagonist?. Arthritis Research, 2004, 6, S12.	2.0	47
171	Etanercept " review of efficacy and safety after five years of clinical use. Therapy: Open Access in Clinical Medicine, 2004, 1, 11-23.	0.2	3
172	Etanercept - review of efficacy and safety after five years of clinical use. Therapy: Open Access in Clinical Medicine, 2004, 1, 11-23.	0.2	1
173	Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis and Rheumatism, 2003, 48, 3230-3236.	6.7	707
174	Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Expert Opinion on Drug Safety, 2003, 2, 347-365.	2.4	19
175	Developing a New Generation of TNF Antagonists for the Treatment of Rheumatoid Arthritis. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2003, 3, 310-318.	3.4	18
176	Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. Journal of Rheumatology, 2003, 30, 691-6.	2.0	66
177	Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Tj ETQq1 1 0.784314 rgBT345verlock	2.0	431
178	Meloxicam. Expert Opinion on Pharmacotherapy, 2002, 3, 1501-1512.	1.8	47
179	Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis and Rheumatism, 2002, 46, 1443-1450.	6.7	664
180	Examining the efficacy of biologic therapy: are there real differences?. Journal of rheumatology Supplement, The, 2002, 65, 27-32.	2.2	4

#	ARTICLE	IF	CITATIONS
181	A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis. New England Journal of Medicine, 2000, 343, 1586-1593.	27.0	1,776
182	A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. New England Journal of Medicine, 1999, 340, 253-259.	27.0	2,044
183	Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)â€“Fc Fusion Protein. New England Journal of Medicine, 1997, 337, 141-147.	27.0	1,586